Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study

被引：0

作者：

Smit, E. ^{[1
]}

Ahn, M-J ^{[2
]}

Dagogo-Jack, I. ^{[3
]}

Felip, E. ^{[4
]}

Gelsomino, F. ^{[5
]}

Johnson, B. ^{[6
]}

Johnson, M. ^{[7
]}

Negrao, M. V. ^{[8
]}

Offin, M. ^{[9
]}

Ramalingam, S. ^{[10
]}

Sanborn, R. ^{[11
]}

Tsao, A. ^{[8
]}

Wilner, K. ^{[12
]}

Alcasid, A. ^{[13
]}

Usari, T. ^{[14
]}

Zhang, X. ^{[15
]}

Riely, G. ^{[9
]}

机构：

[1] Leiden Univ, Med Ctr, Leiden, Netherlands

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] Massachusetts Gen Hosp, Boston, MA USA

[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[5] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[6] Dana Farber Canc Inst, Boston, MA USA

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[11] Providence Canc Inst, Earle A Chiles Res Inst, Providence, RI USA

[12] Pfizer, La Jolla, CA USA

[13] Pfizer, Collegeville, PA USA

[14] Pfizer, Milan, Italy

[15] Pfizer, San Francisco, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

non-small cell lung cancer; encorafenib; binimetinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA06.13

引用

页码：S77 / S78

页数：2

共 35 条

[21] Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
Gallois, C.
Bergen, E. S.
Auclin, E.
Pernot, S.
Higue, J.
Trouilloud, I.
Touchefeu, Y.
Turpin, A.
Mazard, T.
Sartore-Bianchi, A.
Prenen, H.
Alberti, A.
Pilla, L.
Cuissy, S.
Wookey, V.
Perret, A.
Melchior, C.
Artru, P.
Dubreuil, O.
Drouillard, A.
Doat, S.
Lavole, J.
Basile, D.
Perkins, G.
Jary, M.
Stintzing, S.
Jos, J.
Tougeron, D.
Taieb, J.
ESMO OPEN, 2024, 9 (09)
[22] Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
Auliac, Jean-Bernard
Bayle, Sophie
Do, Pascal
Le Garff, Gwenaelle
Roa, Magali
Falchero, Lionel
Huchot, Eric
Quere, Gilles
Jeannin, Gaelle
Metivier, Anne-Cecile
Hobeika, Joelle
Guisier, Florian
Chouaid, Christos
CANCERS, 2020, 12 (12) : 1 - 8
[23] NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
Shin Kobayashi
Hideaki Bando
Akinobu Taketomi
Takeshi Takamoto
Eiji Shinozaki
Manabu Shiozawa
Hiroki Hara
Kentaro Yamazaki
Koji Komori
Nobuhisa Matsuhashi
Takeshi Kato
Yoshinori Kagawa
Mitsuru Yokota
Eiji Oki
Keigo Komine
Shinichiro Takahashi
Masashi Wakabayashi
Takayuki Yoshino
BMC Cancer, 23
[24] Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study
Sakata, Hidenori
Murase, Maki
Kato, Takeshi
Yamaguchi, Kensei
Sugihara, Kenichi
Suzuki, Shigenobu
Yoshino, Takayuki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 139 - 144
[25] Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
Hidenori Sakata
Maki Murase
Takeshi Kato
Kensei Yamaguchi
Kenichi Sugihara
Shigenobu Suzuki
Takayuki Yoshino
International Journal of Clinical Oncology, 2023, 28 : 139 - 144
[26] A plain language summary of the 5-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
di Pietro, Alessandra
Cantey-Kiser, Jean
Edwards, Michelle
Ascierto, Paolo A.
FUTURE ONCOLOGY, 2023, 19 (16) : 1091 - 1098
[27] NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
Kobayashi, Shin
Bando, Hideaki
Taketomi, Akinobu
Takamoto, Takeshi
Shinozaki, Eiji
Shiozawa, Manabu
Hara, Hiroki
Yamazaki, Kentaro
Komori, Koji
Matsuhashi, Nobuhisa
Kato, Takeshi
Kagawa, Yoshinori
Yokota, Mitsuru
Oki, Eiji
Komine, Keigo
Takahashi, Shinichiro
Wakabayashi, Masashi
Yoshino, Takayuki
BMC CANCER, 2023, 23 (01)
[28] POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis
Menzies, Alexander M.
Long, Georgina, V
Kohn, Amiee
Tawbi, Hussein
Weber, Jeffrey
Flaherty, Keith
McArthur, Grant A.
Ascierto, Paolo A.
Pfluger, Yanina
Lewis, Karl
Tsai, Katy K.
Hamid, Omid
Prenen, Hans
Fein, Luis
Wang, Erjian
Guenzel, Carolin
Zhang, Fan
Kleha, Joseph F.
di Pietro, Alessandra
Davies, Michael A.
NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
[29] COLUMBUS-AD: phase III study of adjuvant encorafenib plus binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma
van Akkooi, Alexander C. J.
Hauschild, Axel
Long, Georgina, V
Mandala, Mario
Kicinski, Michal
Govaerts, Anne-Sophie
Klauck, Isabelle
Ouali, Monia
Lorigan, Paul C.
Eggermont, Alexander M. M.
FUTURE ONCOLOGY, 2023, 19 (30) : 2017 - 2027
[30] Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
Chalmers, Anna
Cannon, Laura
Akerley, Wallace
ONCOLOGIST, 2019, 24 (07) : 963 - 972

← 1 2 3 4 →